AmpliFold Capture-and-Release for Sensitive LFAs

Lateral flow assays (LFAs) are widely used because they combine low cost, rapid operation, and minimal instrumentation. Their analytical sensitivity, however, is often constrained by reaction kinetics rather than by the intrinsic affinity of the antibodies or the brightness of the label. Chapman Ho, Clíona McMahon, John-Paul Ayrton, Vijay Chudasama, and Michael R. Thomas introduce a strategy called AmpliFold that separates analyte capture from final signal concentration. The approach is described in ACS Sensors 2025, 10, 9432–9446.

Study Background and Research Question

In a conventional sandwich LFA, a sample migrates through a membrane and encounters labeled detection particles before reaching a test line containing immobilized capture receptors. The useful binding window is short. If the association rate is slow, or if the label is large and diffuses poorly, a substantial fraction of analyte complexes may pass the test line without being captured. Increasing antibody affinity can help, but it does not necessarily solve slow transport, steric accessibility, or limited contact time.

The reference study asks whether an LFA can first collect analyte-bound complexes over a large capture region and then release them for a second, more concentrated binding event. HER2 was selected as a model protein biomarker. The research question is therefore kinetic and architectural: can spatially decoupling initial capture from final detection reduce the demand for rapid test-line association while preserving the simplicity of a paper-based assay?

Key Innovation from the Reference Study

AmpliFold uses triggered capture-and-release rather than relying on a single capture event at a narrow line. Anti-HER2 Fab fragments are modified with a cleavable biotin linker. HER2 is premixed with these Fab conjugates and with fluorescein-tagged anti-HER2 antibody nanoparticles, creating sandwich immunocomplexes. In the first strip, the biotin groups bind polystreptavidin receptors distributed across a relatively large membrane area. This broad capture zone functions as a kinetic reservoir.

After washing, the capture strip is folded into contact with a second detection strip. A thiol-mediated cleavage reaction breaks the disulfide-containing linker and releases the retained complexes. The released material migrates into the detection strip, where a narrower test line provides a high-affinity rebinding environment for the tagged nanoparticles. In effect, the first stage prioritizes recovery of complexes from flowing sample, whereas the second stage prioritizes signal localization.

This design is innovative because it treats LFA sensitivity as a systems problem involving transport, surface area, linker chemistry, and rebinding—not simply as a matter of selecting a higher-affinity antibody. The strategy also uses established protein modification chemistry rather than requiring a new detection modality. The authors describe AmpliFold as a proof-of-concept route for improving assay kinetics in a multistep format.

Methods and Experimental Design Insights

The experimental design combines antibody engineering with controlled membrane architecture. One component was an anti-HER2 Fab conjugated through a cleavable biotin-bearing linker. The paper examines how linker length and the bioconjugation strategy influence the efficiency of analyte-complex release. This is important because a linker must be sufficiently accessible for cleavage while retaining the complex during the initial capture and wash stages.

The signal component consisted of gold nanoparticles decorated with fluorescein-tagged anti-HER2 antibodies. These particles were described as dual-affinity nanoparticles because the antibody–HER2 interaction supports analyte recognition, while the fluorescein-associated interaction contributes to high-affinity rebinding at the detection stage. Nanoparticle size was also considered. Large particles can carry substantial signal, but their diffusivity and surface-binding kinetics can be unfavorable in porous membranes.

The physical assay was assembled as a folding two-strip format. The capture and detection strips were aligned on adhesive tape, and folding initiated strip-to-strip contact after the capture stage. Before assembly, the absorbent pad of the capture strip was removed so that the released complexes could elute toward the detection strip. This arrangement makes the workflow more controllable than a single uninterrupted flow path, although it introduces manual handling and additional steps.

Protocol Parameters

• Complex formation: Premix HER2 with the cleavable anti-HER2 Fab conjugate and fluorescein-tagged anti-HER2 gold nanoparticles before applying the sample to the capture strip, as described in the reference study.
• Initial capture: Use a broad polystreptavidin-containing capture region to retain biotin-presenting sandwich complexes over a larger surface area rather than concentrating all capture in one narrow line.
• Wash stage: The reported workflow washes the test strip three times to remove nonspecifically retained material before linker cleavage; this value is study-specific and should be revalidated for a different membrane or sample matrix.
• Strip folding: Remove the capture-strip absorbent pad before assembling the two-strip device, then fold the capture and detection strips into contact to permit transfer after cleavage.
• Triggered release: Apply a validated thiol-based cleavage condition to break the disulfide-containing linker. The article’s cleavage reagent and conditions should not be assumed to be interchangeable with another reductant without compatibility testing.
• Detection: Read the released complexes at a narrow detection line designed to support high-affinity rebinding and signal concentration.
• Workflow duration: The authors report a rapid overall procedure of less than 30 minutes, although practical timing will depend on membrane, sample, wash, and cleavage conditions.

Core Findings and Why They Matter

The main result is that expanding the initial capture area can compensate for poor association kinetics, particularly when receptor density is low. By allowing complexes to be collected over a larger membrane region and subsequently transferred to a narrow readout line, AmpliFold improves the probability that an analyte-bound label reaches a detectable endpoint. The study reports up to a 16-fold sensitivity improvement when capture receptor density and capture-area distribution were tuned for the AmpliFold format, compared with the corresponding conventional arrangement; see the reference study for the experimental comparison.

The approach also addresses a second challenge: the limited diffusivity and surface-binding behavior of large nanoparticles. Using a 150 nm gold nanoparticle example, the authors observed a 12-fold sensitivity enhancement with AmpliFold for analyte spiked into both buffer and human serum. This result is relevant because nanoparticle labels can provide strong optical signal but may be disadvantaged by slow movement through fibrous membranes. The capture-and-release sequence gives these particles more opportunity to be recovered before final signal development.

Linker design was another meaningful finding. Release efficiency depended on both linker length and the method used to modify the Fab fragments. This indicates that a chemically cleavable connection is not automatically functionally equivalent across constructs. Steric accessibility, residual affinity, conjugation heterogeneity, and the position of modification can all influence whether an immunocomplex is retained during washing and released efficiently afterward.

From an assay-development perspective, the study shifts optimization toward a broader parameter space. Researchers must consider receptor density, capture-zone dimensions, cleavage efficiency, strip alignment, nanoparticle size, and rebinding kinetics together. The reported improvements therefore support a design principle rather than a universal performance multiplier: capture-and-release is most useful when transport or association at the conventional test line is a dominant source of signal loss.

Comparison with Existing Internal Articles

The internal article TCEP Hydrochloride: Mechanism and Applications focuses on the chemical basis of disulfide reduction and its role in protein workflows. That chemistry perspective complements the AmpliFold paper’s emphasis on cleavable linkers, but it should not be read as evidence that the LFA study used TCEP hydrochloride specifically. The reference work reports a thiol-based cleavage step and evaluates linker behavior within its own assay system.

A second related resource, TCEP Hydrochloride: Transforming Reductive Bioconjugation, discusses redox-controlled protein modification and dynamic capture-and-release concepts. Its relevance is conceptual: both workflows depend on designing a reversible or cleavable connection that preserves function during one stage and enables controlled release during another. The ACS Sensors study, however, contributes the LFA-specific evidence for membrane-scale capture, nanoparticle transfer, and test-line rebinding.

Limitations and Transferability

AmpliFold is a proof-of-concept architecture, not a demonstration that every LFA will benefit equally. The study uses HER2 and a defined antibody–nanoparticle system, so performance may change with lower-abundance biomarkers, different epitope geometry, weaker antibody pairs, or complex clinical matrices. Serum spiking is useful for evaluating matrix tolerance, but it does not replace testing with authentic patient samples containing endogenous biomarker concentrations and interfering substances.

The multistep format also creates operational trade-offs. Manual folding, absorbent-pad removal, washing, and cleavage may introduce user-to-user variation. The additional handling could complicate manufacturing, packaging, and regulatory validation compared with a conventional one-strip LFA. A cleavage reagent must be sufficiently selective to release the intended complexes without damaging antibodies, nanoparticles, membrane components, or downstream binding sites.

Why this cross-domain matters, maturity, and limitations

The connection between redox bioconjugation and LFA engineering is scientifically useful because linker cleavage can provide temporal control over when a captured complex becomes mobile again. Nevertheless, a reducing agent validated for protein chemistry is not automatically suitable for a diagnostic strip. Solubility, pH, reaction rate, membrane compatibility, residual reagent effects, nanoparticle stability, and interference with antibody binding all require direct testing. The present evidence supports the capture-and-release principle and the importance of disulfide-linker design; it does not establish a universal reagent substitution or clinical-ready protocol.

Research Support Resources

For analogous disulfide-cleavage and bioconjugation experiments, researchers can evaluate Tris(2-carboxyethyl) phosphine hydrochloride (TCEP hydrochloride), SKU B6055, a water-soluble, thiol-free reducing agent described for selective disulfide bond reduction. Its use in an AmpliFold-like LFA would require assay-specific validation because the reference study used a thiol-based cleavage workflow. The same reagent is also used in protein digestion enhancement and hydrogen-deuterium exchange analysis; separate product information describes broader applications including reduction of dehydroascorbic acid and use as an organic synthesis reducing agent. These applications are practical chemistry resources, not findings of the HER2 LFA study.